Every year, more than one million people face a cancer with no good answer.
BNCT Global is building the infrastructure that changes this. A network of treatment centers globally, anchored by a scientific standard developed over three decades. This document is for those who want to be part of it.
The science
The science works.
Japan has been treating patients
for 50 years.
While Europe debated infrastructure, Japan treated patients. Since the 1970s, Japanese physicians have documented what BNCT can do for cancers that had no other viable option. The protocols are mature. The outcomes are repeated. The national health system has recognized it since 2020. This is not theory. It is 50 years of accumulated proof.
Continuous treatment in Japan since the 1970s. The longest active BNCT programme in the world.
In recurrent head and neck cancers with no remaining treatment options. Conventional radiation therapy is less effective and has severe side effects.
Kankaanranta et al., IJROBP, 2012
Against 14% after stereotactic radiotherapy (Vargo et al., IJROBP 100, 2018).
Koivunoro et al., Radiother Oncol. 137, 2019
Japan's national health system officially reimburses BNCT. Regulatory confirmation that the therapy works.
This is not a new idea.
It is a proven therapy waiting to reach Europe.
Europe is not waiting for proof. Europe is waiting for infrastructure. BNCT Global is building that infrastructure. The science was never the barrier.
Established in
Japan
Coming to
Europe
Prof. Dr. med.
Wolfgang Sauerwein
“We urgently need well-designed clinical trials. The window is open. The technology is ready. Now we act.”
- Principal investigator, European EORTC BNCT trials
- Specially Appointed Professor, Okayama University, Japan
- Order of the Rising Sun, awarded by the Japanese Government
Standardized center design eliminates the regulatory reinvention cost that blocked all previous European attempts.
Each new center generates clinical data that accelerates reimbursement for all others. Solo centers cannot do this.
No network of BNCT centers exists today. The first to set the standard defines it for the continent.
Prof. Sauerwein trained the researchers who built the Japanese system. The evidence exists. The infrastructure did not. Now it will.
The scale of the need
By 2040, cancer will be the leading cause of death globally.
The world is aging. Aging is the single greatest risk factor for cancer. The number of people who will need better treatment is not a projection. It is a demographic certainty.
BNCT is not a niche therapy. It is a platform for the cancers that conventional radiation cannot adequately treat. The addressable population grows every year without any change in the technology.
One reference center. Ten therapy centers. One standard.
A global standard. Starting in Europe.
Phase 1 is what we are raising for. What follows is a separate conversation.
Reference center (location TBD). 10 affiliated therapy centers. Clinical trials for reimbursement approval. Blueprint model proven. The BNCT standard for Europe is written here. This is what we are building and what this investment case covers in full.
Available to qualified investors in the full briefing with Prof. Sauerwein.
Shared exclusively in direct conversation.
Phase 1 stands entirely on its own as an investment case. What follows is not necessary to justify the decision. It is context for those who think in decades.
Next step
This is not a startup pitch.
It is an invitation to build something permanent.
Prof. Sauerwein presents the full case personally. No intermediaries. A 30-minute conversation with the person who built the scientific foundation this company stands on.
BNCT Global GmbH · Essen, Germany · Treat the Impossible